Knowledge Base

What factors should be considered when placing physical distances in the workplace in the event of an infectious disease?

27 December 2023
2 min read

When placing physical distances in the workplace in the event of an infectious disease, it is important to consider several factors. These include:

1.Mode of transmission: The mode of transmission for the infectious disease should be considered. For example, airborne diseases require more distance between individuals than contact-based diseases.

2.Type of work: The type of work that will be done at the workplace should also be taken into account. For example, jobs that involve close proximity with others may require greater physical distancing measures.

3.Size of workspace: The size of the workspace should be considered as well. A larger workspace may allow for greater physical distancing, while a smaller space may require more creative solutions such as staggered shifts or flexible work arrangements.

4.Accessibility: Physical barriers and accessibility should be considered. For example, if physical distancing requires workers to stay behind a barrier, this must be accessible and easy to navigate around.

5.Ventilation: Ventilation plays a significant role in reducing the spread of respiratory illnesses. Good ventilation can help reduce the concentration of virus particles in the air, which can decrease the risk of transmission.

6.Communication: Clear communication about the need for physical distancing and how it will be implemented is essential. This includes providing clear instructions on how to maintain physical distance, who is responsible for enforcing the rules, and what consequences will occur if the rules are not followed.

It is important that it is combined with other public health measures, such as hand and respiratory hygiene, environmental clean-up and disinfection of commonly touched surfaces and objects, ventilation, wearing face masks and a policy of staying at home if unwell. 

Cullinan Oncology begins Phase 1 trial of CLN-617, a novel biologic fusing IL-2 and IL-12 cytokines
Latest Hotspot
3 min read
Cullinan Oncology begins Phase 1 trial of CLN-617, a novel biologic fusing IL-2 and IL-12 cytokines
27 December 2023
Cullinan Oncology has initiated a Phase 1 study of CLN-617, an innovative biologic that combines the properties of IL-2 and IL-12 cytokines
Read →
An analysis of Anlotinib Dihydrochloride's R&D progress and its clinical results presented at the 2023 ESMO_ASIA Annual Meeting
ESMO 2023
4 min read
An analysis of Anlotinib Dihydrochloride's R&D progress and its clinical results presented at the 2023 ESMO_ASIA Annual Meeting
27 December 2023
the latest clinical results of Anlotinib Dihydrochloride were presented in 2023 ESMO_ASIA.
Read →
FDA and EMA acknowledge submission for CSL's innovative Factor XIIa-blocking agent, Garadacimab
Latest Hotspot
3 min read
FDA and EMA acknowledge submission for CSL's innovative Factor XIIa-blocking agent, Garadacimab
27 December 2023
CSL, a major biotech player, announced that the FDA has accepted its application for the once-monthly hereditary angioedema preventative drug, garadacimab (CSL312).
Read →
What are the key principles behind mucoadhesive drug delivery systems?
Knowledge Base
2 min read
What are the key principles behind mucoadhesive drug delivery systems?
27 December 2023
Mucoadhesive drug delivery systems (MDDS) are designed to enhance the residence time of a drug at a specific site in the body, primarily on mucosal surfaces.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.